These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 3116739)

  • 1. Severe bladder contracture in patient receiving intravesical mitomycin C for superficial bladder cancer.
    Baker WC; Russo MA; deVere White RW
    Urology; 1987 Oct; 30(4):357-8. PubMed ID: 3116739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer.
    Drago PC; Badalament RA; Lucas J; Drago JR
    J Urol; 1989 Oct; 142(4):1071-2. PubMed ID: 2507794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severely contracted bladder following intravesical mitomycin C therapy.
    Wajsman Z; McGill W; Englander L; Huben RP; Pontes JE
    J Urol; 1983 Aug; 130(2):340-1. PubMed ID: 6410085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal failure after intravesical mitomycin C.
    Farha AJ; Krauss DJ
    Urology; 1989 Oct; 34(4):216-7. PubMed ID: 2508290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bladder wall calcification after topical mitomycin C.
    Alter AJ; Malek GH
    J Urol; 1987 Nov; 138(5):1239-40. PubMed ID: 3118058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical mitomycin C therapy for superficial bladder cancer. Report of a multicentre phase II study.
    MacFarlane JR; Tolley DA
    Br J Urol; 1985 Feb; 57(1):37-9. PubMed ID: 3918605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of intravesical cisplatin and mitomycin-C for recurrent transitional cell carcinoma of bladder refractory to thiotepa.
    Mobley WC; Loening SA; Narayana AS; Culp DA
    Urology; 1986 Apr; 27(4):335-9. PubMed ID: 3083555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergy to mitomycin C complicating topical administration for urothelial cancer.
    Inglis JA; Tolley DA; Grigor KM
    Br J Urol; 1987 Jun; 59(6):547-9. PubMed ID: 3120846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lung parenchyma disease following instillation of mitomycin C in the bladder].
    Wilhelms E; Criée CP; Neubauer H; Neuhaus KL
    Dtsch Med Wochenschr; 1986 Oct; 111(41):1564-6. PubMed ID: 3095083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pulmonary fibrosis following instillation of mitomycin C in the urinary bladder].
    Neubauer H; Blech M; Wilhelms E; Crieé CP; Neuhaus KL; Truss F
    Urologe A; 1987 Jan; 26(1):41-3. PubMed ID: 3107190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complications of intravesical mitomycin chemotherapy, apropos of 2 clinical case reports].
    Pouya M; Opsomer RJ; Wese FX; Saleh M; Donnay M; Van Cangh PJ
    Acta Urol Belg; 1996 Mar; 64(1):47-53. PubMed ID: 8659335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment schedule of intravesical chemotherapy with mitomycin C in superficial bladder cancer: short-term courses or maintenance therapy.
    van der Meijden AP; DeBruyne FM
    Urology; 1988 Mar; 31(3 Suppl):26-9. PubMed ID: 3126592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of intravesical mitomycin C in the treatment of superficial bladder cancer.
    Harrison GS; Green DF; Newling DW; Richards B; Robinson MR; Smith PH
    Br J Urol; 1983 Dec; 55(6):676-9. PubMed ID: 6418263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder.
    Pavlotsky A; Eidelman A; Barak F; Alon H; Horn Y
    J Surg Oncol; 1989 May; 41(1):9-11. PubMed ID: 2497274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases.
    Smith G; Elton RA; Chisholm GD; Newsam JE; Hargreave TB
    Br J Urol; 1986 Dec; 58(6):659-63. PubMed ID: 3099881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transitional cell carcinoma of the prostate following intravesical therapy for transitional cell carcinoma of the bladder.
    Hardeman SW; Perry A; Soloway MS
    J Urol; 1988 Aug; 140(2):289-92. PubMed ID: 3135420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effects associated with intravesical mitomycin.
    Nissenkorn I; Herrod H; Soloway MS
    J Urol; 1981 Nov; 126(5):596-7. PubMed ID: 6457917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of superficial bladder cancer with intravesical mitomycin C: analysis of immediate and long-term response in 70 patients.
    Soloway MS
    J Urol; 1985 Dec; 134(6):1107-9. PubMed ID: 3932684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
    Heney NM; Koontz WW; Barton B; Soloway M; Trump DL; Hazra T; Weinstein RS
    J Urol; 1988 Dec; 140(6):1390-3. PubMed ID: 3143016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermatitis due to mitomycin C bladder instillations: study of 2 cases.
    Arregui MA; Aguirre A; Gil N; Goday J; Ratón JA
    Contact Dermatitis; 1991 May; 24(5):368-70. PubMed ID: 1832619
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.